April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 15, 2025

Mavacamten Misses Endpoints in nHCM Trial

Mavacamten's phase III trial for nonobstructive hypertrophic cardiomyopathy does not show significant improvement in functional capacity or symptoms, reflecting challenges in less severe populations. Bristol Myers Squibb plans to present full data at a future scientific meeting.

Reuters

April 15, 2025

Tenecteplase Matches Alteplase in Stroke Outcomes

In a registry-based study of 79,550 patients, tenecteplase showed comparable short-term safety and effectiveness to alteplase for acute ischemic stroke, with no significant differences in functional outcomes or hemorrhagic events.

Conexiant

April 14, 2025

Pecans May Lower Cholesterol, Triglycerides

Replacing usual snacks with 57 g/d of pecans for 12 weeks improved lipids and diet quality.

Conexiant

April 10, 2025

Morning Coffee Consumption Linked to Lower Mortality Risk

“Drinking coffee in the morning may be more strongly associated with a lower risk of mortality than drinking coffee later in the day."

Conexiant

April 04, 2025

Warning Signs Before Sudden Cardiac Death

New research identified key clinical indicators that precede sudden arrhythmic death syndrome in patients under 36.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

Clopidogrel Outshines Aspirin After PCI

“In our study, clopidogrel beat aspirin as a lifelong maintenance monotherapy after standard-duration dual antiplatelet therapy."

Conexiant

March 28, 2025

FDA Declines Cardamyst Approval Request

The FDA declined to approve Milestone’s etripamil nasal spray for PSVT, citing manufacturing issues and a need for more data on impurities, but raised no safety or efficacy concerns.

Reuters